Value of branded proton pump inhibitors formulary considerations

P and T

Volumn 36, Issue 7, 2011, Pages 434-445

  Peura, David A ^a   Berardi, Rosemary R ^b   Gonzalez, Javier ^c   Brunetti, Louis ^d  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Catalyst Rx Company   (United States)

^d MedImpact Healthcare Systems Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450; ESOMEPRAZOLE; ISOENZYME; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG BIOAVAILABILITY; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULARY; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENANTIOMER; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HEALTH INSURANCE; HEARTBURN; HUMAN; MAXIMUM PLASMA CONCENTRATION; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH ACID; STOMACH ACID SECRETION; STOMACH PH;

EID: 80052606885     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. El-Serag HB. Time trends of gastroesophageal reflux disease: A systematic review. Clin Gastroenterol Hepatol 2007; 5(1):17-26.
2. Farup C, Kleinman L, Sloan S, et al. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med 2001;161(1):45-52.
3. Locke GR 3rd, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: A population-based study in Olmsted County, Minnesota. Gastroenterology 1997;112(5): 1448-1456.
4. Wahlqvist P, Karlsson M, Johnson D, et al. Relationship between symptom load of gastro-oesophageal reflux disease and healthrelated quality of life, work productivity, resource utilization and concomitant diseases: Survey of a U.S. cohort. Aliment Pharmacol Ther 2008;27(10):960-970.
5. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002;122(5):1500-1511.
6. Wahlqvist P, Reilly MC, Barkun A. Systematic review: The impact of gastro-oesophageal reflux disease on work productivity. Aliment Pharmacol Ther 2006;24(2):259-272.
7. Dubois RW, Aguilar D, Fass R, et al. Consequences of frequent nocturnal gastro-oesophageal reflux disease among employed adults: Symptom severity, quality of life, and work productivity. Aliment Pharmacol Ther 2007;25(4):487-500.
8. Mody R, Bolge SC, Kannan H, Fass R. Effects of gastroesophageal reflux disease on sleep and outcomes. Clin Gastroenterol Hepatol 2009;7(9):953-959.
9. Johnson DA, Katz PO. Nocturnal gastroesophageal reflux disease: Issues, implications, and management strategies. Rev Gastro - enterol Disord 2008;8(2):98-108.
10. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005;100(1):190-200.
11. 2008 Top 200 branded drugs by total prescriptions. SDI/Verispan, VONA. Drug Top 2009; May 14. Available at: http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard//drugtopics/192009/597089/article.pdf.
12. 2008 Top 200 generic drugs by total prescriptions. SDI/Verispan, VONA. Drug Top 2009; May 7. Available at: http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard//drugtopics/192009/597084/article.pdf.
13. Morelli G, Chen H, Rossiter G, et al. An open-label, parallel, multiple- dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with eso - meprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers. Aliment Pharmacol Ther 2011;33(7):845-854 (online January 28, 2011).
14. Delate T, Mager DE, Sheth J, Motheral BR. Clinical and financial outcomes associated with a proton pump inhibitor prior-authorization program in a Medicaid population. Am J Manag Care 2005;11(1):29-36.
15. Ramser KL, Sprabery LR, Hamann GL, et al. Results of an intervention in an academic Internal Medicine Clinic to continue, stepdown, or discontinue proton pump inhibitor therapy related to a Tennessee Medicaid formulary change. J Manag Care Pharm 2009;15(4):344-350.
16. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manag Care 2010;16(9):e228-e234.
17. Murawski MM, Abdelgawad T. Exploration of the impact of preferred drug lists on hospital and physician visits and the costs to Medicaid. Am J Manag Care 2005;11 Spec No. SP35-42.
18. Ovsag K, Hydery S, Mousa SA. Preferred drug lists: Potential impact on healthcare economics. Vasc Health Risk Manag 2008; 4(2): 403-413.
19. Jackevicius CA, Tu JV, Demers V, et al. Cardiovascular outcomes after a change in prescription policy for clopidogrel. N Engl J Med 2008;359(17):1802-1810.
20. Carlton RI, Bramley TJ, Nightengale B, et al. Review of outcomes associated with formulary restrictions: Focus on step therapy. Am J Pharm Benefits 2010;2(1):50-58.
21. WellPoint Next Rx. Prior Authorization of Benefits Guideline Manual. March 9, 2009. Available at: www.bcbsga.com/provider/noapplication/providerservices/downloadforms/notertiary/pw_a092487.pdf. Accessed April 5, 2010.
22. Abourjaily P, Gouveia WA, Selker HP, Zucker DR. Evaluating the nondrug costs of formulary coverage restrictions. Manag Care 2005;14(8):50-57.
23. Scarpignato C, Pelosini I. Review article: The opportunities and benefits of extended acid suppression. Aliment Pharmacol Ther 2006;23(Suppl 2):23-34.
24. Berardi RR. A critical evaluation of proton pump inhibitors in the treatment of gastroesophageal reflux disease. Am J Manag Care 2000;6(9 Suppl):S491-S505.
25. Wittbrodt ET, Baum C, Peura DA. Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis. Clin Exp Gastroenterol 2009;2:117-128.
26. Sachs G, Shin JM, Briving C, et al. The pharmacology of the gastric acid pump: The H+,K+ ATPase. Annu Rev Pharmacol Toxicol 1995;35:277-305.
27. Scarpignato C, Pelosini I, Di Mario F. Acid suppression therapy: Where do we go from here? Dig Dis 2006;24(1-2):11-46.
28. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastro - enterological Association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology 2008;135(4):1383-1391, 1391.e1-e5.
29. Chey WD, Mody RR, Wu EQ, et al. Treatment patterns and symptom control in patients with GERD: U.S. community-based survey. Curr Med Res Opin 2009;25(8):1869-1878.
30. Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: Protonpump inhibitor failure in gastro-oesophageal reflux disease. Where next? Aliment Pharmacol Ther 2005;22(2):79-94.
31. Vaz-da-Silva M, Loureiro AI, Nunes T, et al. Bioavailability and bioequivalence of two enteric-coated formulations of omeprazole in fasting and fed conditions. Clin Drug Investig 2005;25(6):391-399.
32. Bergstrand R, Grind M, Nyberg G, Olofsson B. Decreased oral bioavailability of lansoprazole in healthy volunteers when given with a standardised breakfast. Clin Drug Investig 1995;9(2):67-71.
33. Chey W, Mody R, Izat E. Patient and physician satisfaction with proton pump inhibitors (PPIs): Are there opportunities for improvement? Dig Dis Sci 2010;55(12):3415-3422.
34. Chey WD, Inadomi JM, Booher AM, et al. Primary-care physicians' perceptions and practices on the management of GERD: Results of a national survey. Am J Gastroenterol 2005;100(6):1237-1242.
35. Robinson M, Shaw K. Proton pump inhibitor attitudes and usage: A patient survey. P&T 2002;27(4):202-206.
36. Calleja JL, Bixquert M, Maldonado J. Impact of nocturnal heartburn on quality of life, sleep, and productivity: The SINERGE study. Dig Dis Sci 2007;52(10):2858-2865.
37. Fass R, Mody R, Halpern R, et al. Association between sleep disturbances and gastroesophageal reflux disease-related medical costs among GERD patients. American College of Gastro - enterology Annual Scientific Meeting, San Diego, October 23-29, 2009.
38. Halpern R, Kothari S, Fuldeore M, et al. GERD-related health care utilization, therapy, and reasons for transfer of GERD patients between primary care providers and gastroenterologists in a U.S. managed care setting. Dig Dis Sci 2010;55(2):328-337.
39. Johnson DA, Orr WC, Crawley JA, et al. Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: A randomized, placebo-controlled trial. Am J Gastroenterol 2005; 100(9):1914-1922.
40. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Adverse risksassociated with proton pump inhibitors: A systematic review. Gastroenterol Hepatol 2009;5(10):725-734.
41. FDA. Possible increased risk of fractures of the hip, wrist, and spine with the use of the proton pump inhibitors. May 25, 2010. Available at: www.fda.gov/Drugs/Drug Safety/Postmarket-DrugSafetyInformationforPatientsandProviders/ucm213206.htm. Accessed May 27, 2010.
42. Ishizaki T, Horai Y. Review article: Cytochrome P450 and the metabolism of proton pump inhibitors: Emphasis on rabeprazole. Aliment Pharmacol Ther 1999;13(Suppl 3):27-36.
43. Information for Healthcare Professionals: Update to the labeling of clopidogrel bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). November 17, 2009. Available at: www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm190787.htm. Accessed March 4, 2010.
44. Plavix (clopidogrel bisulfate), prescribing information. Bridgewater, N.J.: Bristol-Myers Squibb/Sanofi-aventis; 2009.
45. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 [AmericanCollege of Cardiology Foundation, American Collegeof Gastroenterology, and American Heart Association] expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: A focused update of the ACCF/ ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 2010;105(12):2533-2549.
46. Humphries TJ, Merritt GJ. Review article: Drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther 1999;13(Suppl 3):18-26.
47. Vakily M, Lee RD, Wu J, et al. Drug interaction studies with dexlansoprazole modified release (TAK-390 MR), a proton pump inhibitor with a dual delayed-release formulation: Results of four randomized, double-blind, crossover, placebo-controlled, singlecentre studies. Clin Drug Investig 2009;29(1):35-50.
48. Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: Randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther 2011;89(1):65-74.
49. Cuisset T, Frere C, Quilici J, et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose: The PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol 2009;54(13):1149-1153.
50. Olbe L, Carlsson E, Lindberg P. A proton-pump inhibitor expedition: The case histories of omeprazole and esomeprazole. Nat Rev Drug Discov 2003;2(2):132-139.
51. Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: A five-way crossover study. Am J Gastroenterol 2003;98(12):2616-2620.
52. Metz DC, Vakily M, Dixit T, Mulford D. Review article: Dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Aliment Pharmacol Ther 2009;29(9):928-937.
53. Vakily M, Zhang W, Wu J, et al. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: A combined analysis of randomized controlled clinical trials. Curr Med Res Opin 2009; 25(3):627-638.
54. Laine L, Katz PO, Johnson DA, et al. Randomised clinical trial: A novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis. The results of two double-blind studies. Aliment Pharmacol Ther 2011;33(2):203-212.
55. Howden CW. Review article: Immediate-release proton-pump inhibitor therapy. Potential advantages. Aliment Pharmacol Ther 2005;22(Suppl 3):25-30.
56. McDonagh MS, Carson S, Thakurta S. Drug Class Review on Proton Pump Inhibitors. Portland, Ore: Oregon Health & Science University; May 2009.
57. Gralnek IM, Dulai GS, Fennerty MB, Spiegel BM. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: A meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol 2006;4(12):1452-1458.
58. Eggleston A, Katelaris PH, Nandurkar S, et al. Clinical trial: The treatment of gastro-oesophageal reflux disease in primary care. Prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg. Aliment Pharmacol Ther 2009;29(9): 967-978.
59. Jones R, Patrikios T. The effectiveness of esomeprazole 40 mg in patients with persistent symptoms of gastro-oesophageal reflux disease following treatment with a full dose proton pump inhibitor. Int J Clin Pract 2008;62(12):1844-1850.
60. Hoogendoorn RJ, Groeneveld L, Kwee JA. Patient satisfaction with switching to esomeprazole from existing proton pump inhibitor therapy for gastro-oesophageal reflux disease: An observational, multicentre study. Clin Drug Investig 2009;29(12):803-810.
61. Metz DC, Howden CW, Perez MC, et al. Clinical trial: Dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. Aliment Pharmacol Ther 2009;29(7):742-754.
62. Fass R, Chey W, Zakko S, et al. Clinical trial: The effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2009;29(12):1261-1272.
63. Fennerty MB, Johanson JF, Hwang C, Sostek M. Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 2005; 21(4):455-463.
64. Sharma P, Shaheen NJ, Perez MC, et al. Clinical trials: Healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation. Results from two randomized controlled studies. Aliment Pharmacol Ther 2009;29(7):731-741.
65. Lee RD, Vakily M, Mulford D, et al. Clinical trial: The effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor. Evidence for dosing flexibility. Aliment Pharmacol Ther 2009;29(8):824-833.
66. Yasuda S, Ohnishi A, Ogawa T, et al. Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers. Int J Clin Pharmacol Ther 1994;32(9):466-473.
67. Youssef N, Alemayehu B, Ke X, Crawley J. Healthcare costs and utilization implications of exclusion of esomeprazole from a preferred formulary list of a national health plan. American College of Gastroenterology Annual Scientific Meeting, San Diego, October 23-29, 2009.
68. Gosselin A, Luo R, Lohoues H, et al. The impact of proton pump inhibitor compliance on health-care resource utilization and costs in patients with gastroesophageal reflux disease. Value Health 2009;12(1):34-39.
69. Fass R, Johnson DA, Orr WC, et al. The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD. Am J Gastroenterol 2011; 106:421-431.
70. Moayyedi P, Armstrong D, Hunt RH, et al. The gain in qualityadjusted life months by switching to esomeprazole in those with continued reflux symptoms in primary care: EncomPASS. A cluster- randomized trial. Am J Gastroenterol 2010;105(11):2341-2346.
71. Fass R, Mody R, Halpern R, et al. Impact of proton pump inhibitor dosing on PPI utilization patterns among patients with gastro esophageal reflux disease (Abstract 1123). Am J Gastro - enterol 2009;104(Suppl 3):S413.
72. Van Soest EM, Siersema PD, Dieleman JP, et al. Persistence and adherence to proton pump inhibitors in daily clinical practice. Aliment Pharmacol Ther 2006;24(2):377-385.
73. Gleason PP. Assessing step-therapy programs: A step in the right direction. J Manag Care Pharm 2007;13(3):273-275.